



FDA's Review of Genetic Tests

David W. Feigal, M.D., M.P.H.

Director, Center for Devices and
Radiological Health, FDA



APRIL 22, 2002

Powell's Mission Impossible



HOW
MEDICAL
TESTING
HAS TURNED
MILLIONS OF
US INTO ...

HUMAN
GUINEA
PIGS



www.time.com AOL Keyword: TIME

“Thanks to a patchwork regulatory system, perhaps a quarter of all research gets no federal oversight whatsoever.”

Medical Device Definition

An instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is:

- 1) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease in man, or
- 2) intended to affect the structure or any function of the body of man



FDA Consumer Protection

Basic Protections

➤ Risk/Benefit Management

- First human use
- Safe experimental use (product development)
- Widespread use (market approval)
- Adverse experience evaluation
- Corrective actions (recalls, warnings, market withdrawal)

➤ Science-Based Regulatory Decisions


- Evidence-based standards (Safe and Effective)

➤ Integrity assurance


- Enforcement
 - Fraud
 - Bad Manufacturing Practices
 - Research Misconduct



Diagnostic Device Life-Cycle



Diagnostic Device Life-Cycle



ASR Rule

Manufacturer Responsibilities


- Manufacturers must register and list, follow Quality System Regulations (QSR's)
- Sales restricted to high complexity labs
- Labs must establish performance and label accordingly
- Most ASRs are exempt from premarket review
- MDR Reporting to FDA required (adverse experiences)

Lab Responsibilities


- High complexity labs
- Establish performance
- Label as in house test
- Mandatory labeling
- Discretionary labeling



Diagnostic Device Life-Cycle



Informed Consent
IRB oversight
Protocol



Quality System
Design Controls
CAPA: Corrective
and Preventive Actions
MDR Reporting

IVD Equipment
and Kit
Manufacturers




FDA Oversight

- Design controls call for identification of inputs and outputs
- Require verification and validation of device performance
- Require monitoring of device performance



Diagnostic Device Life-Cycle

Class I: No review
Class II: 510(k)
Class III: PMA



MDR Reporting
Recalls
Labeling Revisions




FDA Risk Assessment

Across the Diagnostic Life Cycle


- Investigational use
- Premarket review
- Requirement for production using quality system regulations (good manufacturing practices)
- Medical device reporting
- Recalls and Safety Alerts




Device Regulatory Path



Device Regulatory Path



Device Regulatory Path



In House Tests

- Established practice
- Long history
- Regulated by CLIA

Analyte Specific Reagents

- Building blocks or active ingredients of in house tests
- Designed to allow for in house tests under incremental control
- Classification



Regulatory Gap

CLIA is system oriented and focuses on analytical performance and QC

➤ No definition of “investigational”

FDA is device specific and focuses on analytical and clinical performance; it requires manufacturing quality standards



FDA and Safety: Basic Strategies

FDA Consumer Protection Tools


- Truth-in-Labeling
- Premarket Safety Controls
- Premarket Efficacy Controls
- Postmarket Study Requirements
- Postmarket “Event” Reporting
- Standards Conformance



Oversight of *In Vitro* Diagnostics



Center for
Devices
and
Radiological
Health



Medical
Devices



Health
Professionals



Health
Facilities

IRB's

Clinical
Laboratories
Improvement
Amendments
(CLIA) Program

States

